Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 6/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.40 |
| ▸ | SMOX | Q9NWM0 | 2/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 2/20 | 0.31 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.30 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353525 | 0.89 | MAOA (0.44) | MAOAKDM1ARCOR1SMOXSERPINE1 | |
| SCHEMBL16995658 | 0.87 | KDM1A (0.43) | MAOAKDM1ARCOR1SMOXLCK | |
| SCHEMBL16995670 | 0.80 | KDM1A (0.46) | KDM1ARCOR1SMOXLCKBTK | |
| SCHEMBL16995675 | 0.77 | KDM1A (0.45) | KDM1ARCOR1SMOXEIF2AK1 | |
| SCHEMBL16995660 | 0.77 | KDM1A (0.49) | MAOAKDM1ARCOR1SMOX | |
| SCHEMBL16995666 | 0.76 | KDM1A (0.48) | KDM1ARCOR1SMOXEIF2AK1 | |
| SCHEMBL16995714 | 0.76 | KDM1A (0.64) | MAOAKDM1ARCOR1SMOXFABP4 | |
| SCHEMBL18359064 | 0.76 | KDM1A (0.42) | KDM1ARCOR1SMOXFABP4EGFR | |
| SCHEMBL16995682 | 0.75 | KDM1A (0.47) | MAOAKDM1ARCOR1SMOXFABP4 | |
| SCHEMBL16995673 | 0.75 | L3MBTL1 (0.42) | KDM1ARCOR1SMOXLCKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015120281-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | KDM1A, KDM1B, KDM3A | MAOA 352/4885KDM1A 1/4885RCOR1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.